Merck's Biosims Business: What's For Sale And Who Will Buy It?
Merck KGaA is getting out of biosimilars – a unit that CEO Stefan Oschmann called the company's now redundant back up plan – to instead focus on its growing oncology pipeline, which includes recently acquired pipeline candidates from Vertex Pharma.
You may also be interested in...
There are 20 biosimilar adalimumab drugs in development – including one from Amgen that has already been approved but not yet launched. Biotechs and big pharma companies alike are lining up their candidates in preparation for when AbbVie's world-leading inflammation and immunology product Humira loses patent protection.
Graphical timeline tracks the deals that shaped the two firms from turn of the last century to the present day.
For In Vivo's 16th annual Deals of the Year contest, we selected 12 nominees in three categories – Top Alliance, Top Financing and Top M&A. The polls are closed, and it is time to reveal the winners.